GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(®) natural killer (NK) cell engager platform, today announced that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ.

Presentation Title: Inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK cell immunotherapy Abstract No.: 655 Presenter: Paarth Dodhiawala, University of Minnesota Medical School(1) Presentation Date: Friday, November 6, 2026 Presentation Time: 3:05-3:20 PM MT Location: North Building – 300 Level – Halls BC Session 106a: Combination Therapies Involving Cell Therapy, 1:45-3:25 PM MST Session Description: While cell therapy has transformed the treatment of certain hematologic malignancies, its impact in solid tumors remains limited by antigen heterogeneity, immunosuppressive microenvironments, and nutrient deprivation. As efforts to engineer more effective immune cells continue, there is growing interest in combining cell therapies with complementary approaches to enhance their function and engage endogenous immunity. This session will highlight diverse strategies to extend the clinical impact of cell therapies through rational combination approaches. Session Schedule: https://www.sitcancer.org/2026/schedule/sitc-2026-schedule#session-1596